Latest Medicure Inc (MCUJF) Headlines Innovat
Post# of 7
Posted On: 03/10/2014 12:57:38 PM
Latest Medicure Inc (MCUJF) Headlines
Innovative Food Holdings, Inc. Presents at MicroCapClub Invitational
Marketwire - Tue Feb 04, 7:45AM CST
Innovative Food Holdings, Inc. (OTCQB: IVFH) announced today it has been selected to present at the 2nd annual MicroCapClub Invitational.
Medicure Reports Second Quarter Financial Results for Fiscal 2014
Marketwire - Tue Jan 28, 3:31PM CST
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the second quarter ended November 30, 2013.
Beer in Hungary
M2 - Wed Jan 22, 3:28AM CST
After a difficult period for the beer industry in Hungary caused by the negative effects of the economic crisis on consumer purchasing power, the decline in beer consumption started to turn around in 2011 and in 2012, beer sales continued to grow in both value and volume terms. Volume sales surpassed 700 million litres, but this is still a long way from the volume sales of five years ago. Due to stable demand by beer consumers further recovery is expected.
Beer in India
M2 - Wed Jan 22, 3:28AM CST
Beer sales posted a growth of 11% in terms of total volume, spurred by a hot summer of 2012 and rising prices of competing liquor like spirits and wine. In addition, a crackdown by state governments on illegal spirits and country liquor also caused a shift to branded beer.
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Medicure Reports First Quarter Financial Results for Fiscal 2014
Marketwire - Wed Oct 30, 10:30AM CDT
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the first quarter ended August 31, 2013.
IIROC Trade Resumption - Medicure Inc.
Newsfile Corp - Fri Oct 11, 9:40AM CDT
Trading resumes in:
Medicure Announces Approval of Recommended Dosing Regimen for AGGRASTAT(R)
Marketwire - Fri Oct 11, 9:29AM CDT
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(OTCQB: MCUJF), is pleased to announce that the United States Food and Drug Administration (FDA) has approved the AGGRASTAT(R) (tirofiban HCl) high-dose bolus (HDB) regimen, as requested under Medicure's supplemental New Drug Application (sNDA). The AGGRASTAT HDB regimen (25 mcg/kg over 3 minutes, followed by 0.15 mcg/kg/min) now becomes the recommended dosing for the reduction of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome (NSTE-ACS).
IIROC: Halt, Medicure Inc.
Marketwire Canada - Fri Oct 11, 9:07AM CDT
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants :
IIROC Trade Halt - Medicure Inc.
Newsfile Corp - Fri Oct 11, 9:02AM CDT
The following issues have been halted by IIROC:
Acute Coronary Syndrome - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t22wlp/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H2 2013" report to their offering. 'Acute Coronary Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome. Scope - A snapshot of the global therapeutic scenario for Acute Coronary Syndrome. - A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Coronary Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. AstraZeneca PLC GlaxoSmithKline plc Pfizer Inc. Bayer AG Ligand Pharmaceuticals Incorporated Medicure Inc. Arena Pharmaceuticals, Inc. CSL Limited LG Life Sciences, Ltd Auspex Pharmaceuticals Viron Therapeutics, Inc. Regado Biosciences. Cerenis Therapeutics SA Lacer, S.A. Lee's Pharmaceutical Holdings Limited Ampio Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/t2...e_coronary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Medicure Announces Grant of Options
Marketwire - Fri May 10, 2:43PM CDT
Medicure Inc. (the "Company") (TSX VENTURE: MPH)(PINKSHEETS: MCUJD) announces today that the Board of Directors has approved the grant of an aggregate of 463,000 options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to the Company's Stock Option Plan. These options entitle the holders thereof to acquire, on or before the tenth anniversary of the date of grant, up to 463,000 common shares of the Company at an exercise price of $0.30 per share. The options are subject to the approval of the TSX Venture Exchange. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to a resale restriction for a period of four months from the date of grant of the underlying option.
Medicure Reports Third Quarter Financial Results for Fiscal 2013
Marketwire - Mon Apr 29, 3:31PM CDT
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(PINKSHEETS: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended February 28, 2013.
Dr. Albert D. Friesen to File Early Warning Report
Marketwire - Thu Feb 28, 6:31AM CST
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(PINKSHEETS: MCUJF), a specialty pharmaceutical company, today reports that since July 18, 2011 Dr. Albert D. Friesen has acquired shares exceeding 2% of the outstanding common shares of Medicure. This 2% reporting threshold was reached on February 27, 2013 with the acquisition of 6,000 common shares of Medicure representing approximately 0.05% of the Company's outstanding common shares (the "Acquisition"). The shares were purchased at a price of $0.34 per share through the facilities of the TSX Venture Exchange for investment purposes. Dr. Friesen may in the future acquire additional shares in the Company, if deemed appropriate to do so in his sole discretion.
Innovative Food Holdings, Inc. Presents at MicroCapClub Invitational
Marketwire - Tue Feb 04, 7:45AM CST
Innovative Food Holdings, Inc. (OTCQB: IVFH) announced today it has been selected to present at the 2nd annual MicroCapClub Invitational.
Medicure Reports Second Quarter Financial Results for Fiscal 2014
Marketwire - Tue Jan 28, 3:31PM CST
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the second quarter ended November 30, 2013.
Beer in Hungary
M2 - Wed Jan 22, 3:28AM CST
After a difficult period for the beer industry in Hungary caused by the negative effects of the economic crisis on consumer purchasing power, the decline in beer consumption started to turn around in 2011 and in 2012, beer sales continued to grow in both value and volume terms. Volume sales surpassed 700 million litres, but this is still a long way from the volume sales of five years ago. Due to stable demand by beer consumers further recovery is expected.
Beer in India
M2 - Wed Jan 22, 3:28AM CST
Beer sales posted a growth of 11% in terms of total volume, spurred by a hot summer of 2012 and rising prices of competing liquor like spirits and wine. In addition, a crackdown by state governments on illegal spirits and country liquor also caused a shift to branded beer.
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Medicure Reports First Quarter Financial Results for Fiscal 2014
Marketwire - Wed Oct 30, 10:30AM CDT
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the first quarter ended August 31, 2013.
IIROC Trade Resumption - Medicure Inc.
Newsfile Corp - Fri Oct 11, 9:40AM CDT
Trading resumes in:
Medicure Announces Approval of Recommended Dosing Regimen for AGGRASTAT(R)
Marketwire - Fri Oct 11, 9:29AM CDT
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(OTCQB: MCUJF), is pleased to announce that the United States Food and Drug Administration (FDA) has approved the AGGRASTAT(R) (tirofiban HCl) high-dose bolus (HDB) regimen, as requested under Medicure's supplemental New Drug Application (sNDA). The AGGRASTAT HDB regimen (25 mcg/kg over 3 minutes, followed by 0.15 mcg/kg/min) now becomes the recommended dosing for the reduction of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome (NSTE-ACS).
IIROC: Halt, Medicure Inc.
Marketwire Canada - Fri Oct 11, 9:07AM CDT
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants :
IIROC Trade Halt - Medicure Inc.
Newsfile Corp - Fri Oct 11, 9:02AM CDT
The following issues have been halted by IIROC:
Acute Coronary Syndrome - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t22wlp/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H2 2013" report to their offering. 'Acute Coronary Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome. Scope - A snapshot of the global therapeutic scenario for Acute Coronary Syndrome. - A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Coronary Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. AstraZeneca PLC GlaxoSmithKline plc Pfizer Inc. Bayer AG Ligand Pharmaceuticals Incorporated Medicure Inc. Arena Pharmaceuticals, Inc. CSL Limited LG Life Sciences, Ltd Auspex Pharmaceuticals Viron Therapeutics, Inc. Regado Biosciences. Cerenis Therapeutics SA Lacer, S.A. Lee's Pharmaceutical Holdings Limited Ampio Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/t2...e_coronary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Medicure Announces Grant of Options
Marketwire - Fri May 10, 2:43PM CDT
Medicure Inc. (the "Company") (TSX VENTURE: MPH)(PINKSHEETS: MCUJD) announces today that the Board of Directors has approved the grant of an aggregate of 463,000 options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to the Company's Stock Option Plan. These options entitle the holders thereof to acquire, on or before the tenth anniversary of the date of grant, up to 463,000 common shares of the Company at an exercise price of $0.30 per share. The options are subject to the approval of the TSX Venture Exchange. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to a resale restriction for a period of four months from the date of grant of the underlying option.
Medicure Reports Third Quarter Financial Results for Fiscal 2013
Marketwire - Mon Apr 29, 3:31PM CDT
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(PINKSHEETS: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended February 28, 2013.
Dr. Albert D. Friesen to File Early Warning Report
Marketwire - Thu Feb 28, 6:31AM CST
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(PINKSHEETS: MCUJF), a specialty pharmaceutical company, today reports that since July 18, 2011 Dr. Albert D. Friesen has acquired shares exceeding 2% of the outstanding common shares of Medicure. This 2% reporting threshold was reached on February 27, 2013 with the acquisition of 6,000 common shares of Medicure representing approximately 0.05% of the Company's outstanding common shares (the "Acquisition"). The shares were purchased at a price of $0.34 per share through the facilities of the TSX Venture Exchange for investment purposes. Dr. Friesen may in the future acquire additional shares in the Company, if deemed appropriate to do so in his sole discretion.
(0)
(0)